The most common adverse reactions (reported in ≥5% of patients) were:
For Full Prescribing Information, please click here.
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
Further information about Puma Biotechnology may be found at www.pumabiotechnology.com
To learn about NERLYNX (neratinib) tablets, visit www.NERLYNX.com